Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Supernus Pharm 9715 Key West Avenue ROCKVILLE MD 20850 USA

www.supernus.com Employees: 778 P: 301-838-2500

Sector:

Medical

Description:

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 2,841,672
Enterprise Value, $K 2,713,222
Shares Outstanding, K 57,582
Float, K 52,515
% Float 91.20%
Short Interest, K 4,189
Short Float 7.27%
Days to Cover 6.51
Short Volume Ratio 0.58
% of Insider Shareholders 8.80%

Financials:

Annual Sales, $ 718,950 K
Annual Net Income, $ -38,550 K
Last Quarter Sales, $ 211,570 K
Last Quarter Net Income, $ -4,110 K
EBIT, $ 27,170 K
EBITDA, $ 117,200 K

Growth:

1-Year Return 59.52%
3-Year Return 33.05%
5-Year Return 74.32%
5-Year Revenue Growth 38.15%
5-Year Earnings Growth -5.08%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.92 on 02/24/26
Next Earnings Date 05/05/26
Earnings Per Share ttm 2.27
EPS Growth vs. Prev Qtr 63.04%
EPS Growth vs. Prev Year 22.95%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

SUPN Ratios

Ratio
Price/Earnings ttm 21.82
Price/Earnings forward 27.43
Price/Earnings to Growth 1.54
Return-on-Equity % 12.26%
Return-on-Assets % 9.21%
Profit Margin % -5.36%
Debt/Equity 0.00
Price/Sales 3.97
Price/Cash Flow 13.12
Price/Book 2.67
Book Value/Share 18.52
Interest Coverage -0.90
60-Month Beta 0.70
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.